Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K

[Development of allogeneic CAR T-cells].

Vincent Alcazer1, Stéphane Depil2

  • 1Centre de recherche en cancérologie, 28, rue Laennec, 69008 Lyon, France; Hospices civils de Lyon, centre hospitalier Lyon Sud, service d'hématologie, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France.

Bulletin Du Cancer
|December 18, 2021
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology.

Blood·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia.

HemaSphere·2025
Same author

The pivotal role of immune functional assays in deciphering immune function alterations.

Clinical and experimental immunology·2025
Same author

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

Journal for immunotherapy of cancer·2025

Allogeneic CAR T-cell therapy offers advantages over autologous treatments but faces challenges like graft-versus-host disease. This review explores methods to overcome these hurdles for effective CAR T-cell treatments.

Area of Science:

  • Immunology
  • Cell Therapy
  • Hematology

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy is a significant advancement in hematology.
  • Allogeneic CAR T-cells, derived from donors, present potential benefits including immediate availability and cost reduction compared to autologous CAR T-cells.

Purpose of the Study:

  • To review strategies for producing allogeneic CAR T-cells that minimize graft-versus-host disease (GvHD) and enhance persistence in recipients.
  • To present preliminary clinical findings of first-generation allogeneic CAR T-cells.

Main Methods:

  • Review of current scientific literature and clinical trial data on allogeneic CAR T-cell production and application.
  • Analysis of different approaches to engineer allogeneic T-cells for reduced immunogenicity and improved engraftment.
Keywords:
Allogeneic T-cellCAR T-cellCAR-TCellules T allogéniquesGene editingImmunotherapyImmunothérapieLymphocyte T virus-spécifiqueVirus-specific T-cellÉdition génique

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

861
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

4.0K

Related Experiment Videos

Last Updated: Oct 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

861
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

4.0K

Main Results:

  • Allogeneic CAR T-cells face challenges including GvHD and host immune rejection due to foreign immunological identities.
  • Various strategies are being developed to mitigate these risks and improve therapeutic efficacy.

Conclusions:

  • Developing 'off-the-shelf' allogeneic CAR T-cell therapies requires overcoming immunological barriers to enable widespread clinical use.
  • Further research and clinical evaluation are essential to realize the full potential of allogeneic CAR T-cells in treating hematological malignancies and solid tumors.